Watson Bio: Subsidiary receives Drug Clinical Trial Approval Notice for freeze-dried herpes zoster virus mRNA vaccine.

Watson Biotech announced that its subsidiaries, Beijing Watson Innovative Biotechnology Co., Ltd., Yunnan Vaccine Laboratory Co., Ltd., Yuxi Watson Biotechnology Co., Ltd., jointly developed and applied for clinical trials for a freeze-dried herpes zoster virus mRNA vaccine with Fudan University and Shanghai Blue Jay Biopharmaceutical Co., Ltd. The company recently obtained a "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration. The notice numbers are: 2025LP03354; 2025LP03355. Registration classification: Preventive biological products. Approval conclusion: According to the "Drug Administration Law of the People's Republic of China", the "Vaccine Administration Law of the People's Republic of China", and related regulations, the freeze-dried herpes zoster virus mRNA vaccine submitted for review on September 18, 2025 meets the requirements for drug registration and is approved to conduct clinical trials for the prevention of herpes zoster.